The Performance of the Upper Limb scores correlate with pulmonary function test measures and Egen Klassifikation scores in Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 26, Issue 4-5, 2016, Pages 264-271

  Lee, Ha Neul ^a   Sawnani, Hemant ^a   Horn, Paul S ^a   Rybalsky, Irina ^a   Relucio, Lani ^a   Wong, Brenda L ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Duchenne muscular dystrophy; Egen Klassifikation; Long term glucocorticoid treatment; Non ambulatory; Pulmonary function test; The Performance of the Upper Limb

Indexed keywords

DEFLAZACORT; PREDNISONE; GLUCOCORTICOID; MUSCLE RELAXANT AGENT;

ADOLESCENT; ADULT; ARM; ARTICLE; BODY MASS; CARDIOPULMONARY FUNCTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DUCHENNE MUSCULAR DYSTROPHY; EGEN KLASSIFIKATION SCALE; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; LONG TERM CARE; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MAXIMAL EXPIRATORY PRESSURE; MAXIMAL INSPIRATORY PRESSURE; PEAK COUGH FLOW; PRIORITY JOURNAL; RANGE OF MOTION; RESPIRATORY TRACT PARAMETERS; UPPER LIMB SCALE; COMPARATIVE STUDY; JOINT CHARACTERISTICS AND FUNCTIONS; LUNG; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; UPPER LIMB; YOUNG ADULT;

ADOLESCENT; ADULT; BODY MASS INDEX; CHILD; CROSS-SECTIONAL STUDIES; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; MUSCULAR DYSTROPHY, DUCHENNE; NEUROMUSCULAR AGENTS; RANGE OF MOTION, ARTICULAR; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; UPPER EXTREMITY; YOUNG ADULT;

EID: 84962006746     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2016.02.015     Document Type: Article

References (49)

1. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9(1):77-93.
2. Henricson E.K., Abresch R.T., Cnaan A., et al. The Cooperative International Neuromuscular Research Group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 2013, 48(1):55-67.
3. McDonald C.M., Henricson E.K., Abresch R.T., et al. The Cooperative International Neuromuscular Research Group Duchenne natural history study - a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 2013, 48(1):32-54.
4. Moxley R.T., Pandya S., Ciafaloni E., Fox D.J., Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010, 25(9):1116-1129.
5. Moxley R.T., Ashwal S., Pandya S., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005, 64(1):13-20.
6. Manzur A.Y., Kuntzer T., Pike M., Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008, (1). CD003725.
7. Biggar W.D., Harris V.A., Eliasoph L., Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006, 16(4):249-255.
8. Markham L.W., Kinnett K., Wong B.L., Woodrow Benson D., Cripe L.H. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008, 18(5):365-370.
9. Silversides C.K., Webb G.D., Harris V.A., Biggar D.W. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003, 91(6):769-772.
10. Schram G., Fournier A., Leduc H., et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 2013, 61(9):948-954.
11. Dec G.W. Steroid therapy effectively delays Duchenne's cardiomyopathy. J Am Coll Cardiol 2013, 61(9):955-956.
12. Machado D.L., Silva E.C., Resende M.B., Carvalho C.R., Zanoteli E., Reed U.C. Lung function monitoring in patients with Duchenne muscular dystrophy on steroid therapy. BMC Res Notes 2012, 5:435.
13. Mayhew A., Mazzone E.S., Eagle M., et al. Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 2013, 55(11):1038-1045.
14. Mazzone E., Martinelli D., Berardinelli A., et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010, 20(11):712-716.
15. McDonald C.M., Henricson E.K., Abresch R.T., et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important difference form a multicenter study. Muscle Nerve 2013, 48(3):357-368.
16. Mazzone E., Vasco G., Sormani M.P., et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 2011, 77(3):250-256.
17. Goemans N., van den Hauwe M., Wilson R., van Impe A., Klingels K., Buyse G. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subject on daily corticosteroids. Neuromuscul Disord 2013, 23:618-623.
18. Bushby K., Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond) 2011, 1(9):1217-1235.
19. Merkies I.S., Faber C.G. Outcome measures in Duchenne muscular dystrophy: are we ready for the new therapeutic era?. Neuromuscul Disord 2009, 19(6):447.
20. Mercuri E., McDonald C., Mayhew A., et al. International workshop on assessment of upper limb function in Duchenne muscular dystrophy (Rome). Neuromuscul Disord 2012, 22(11):1025-1028.
21. Mazzone E.S., Vasco G., Palermo C., et al. A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. Dev Med Child Neurol 2012, 54(10):879-885.
22. Mercuri E., Mazzone E. Choosing the right clinical outcome measure: from the patient to the statistician and back. Neuromuscul Disord 2011, 21(1):16-19.
23. Pane M., Mazzone E.S., Fanelli L., et al. Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord 2014, 24(3):201-206.
24. Roberto R., Fritz A., Hagar Y., et al. The natural history of cardiac and pulmonary function decline in patients with Duchenne musculary dystrophy. Spine 2011, 36(15):E1009-17.
25. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9(2):177-189.
26. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995, 74(5 Suppl.):S70-92.
27. Sharma G. Pulmonary function testing in neuromuscular disorders. Pediatrics 2009, 123(Suppl. 4):S219-21.
28. Phillips M.F., Quinlivan R.C., Edwards R.H., Calverley P.M. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 2001, 164(12):2191-2194.
29. Lyager S., Steffensen B., Juhl B. Indicators of need for mechanical ventilation in Duchenne muscular dystrophy and spinal muscular atrophy. Chest 1995, 108(3):779-785.
30. Mayhew J.E., Florence J.M., Mayhew T.P., et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve 2007, 35(1):36-42.
31. th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003, 13(2):166-172.
32. Otto R.K., Ferguson M.R., Friedman S.D. Recent advancements in neuromuscular medicine cardiac MRI in muscular dystrophy: an overview and future directions. Phys Med Rehabil Clin N Am 2012, 23(1):123-132.
33. Steffensen B.F., Hyde S.A., Attermann J., Mattsson E. Reliability of the EK scale, a functional test for non-ambulatory persons with Duchenne dystrophy. Adv Physiother 2002, 4:37-47.
34. Steffensen B., Hyde S., Lyager S., Mattsson E. Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int 2001, 6(3):119-134.
35. Steffensen B.F., Lyager S., Werge B., Rahbek J., Mattsson E. Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy: a longitudinal study. Dev Med Child Neurol 2002, 44(9):623-632.
36. Brunherotti M.A., Sobreira C., Rodrigues-Junior A.L., de Assis M.R., Terra Filho J., Baddini Martinez J.A. Correlations of Egen Klassifikation and Barthel Index scores with pulmonary function parameters in Duchenne muscular dystrophy. Heart Lung 2007, 36(2):132-139.
37. Miller M.R., Hankinson J., Brusasco V., et al. Standardisation of spirometry. Eur Respir J 2005, 26(2):319-338.
38. Pellegrino R., Viegi G., Brusasco V., et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26(5):948-968.
39. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993, 15(2):75-88.
40. Mayhew A.G., Eagle M., Steffenson B. S.P.6 Exploratory Rasch analysis of the EK2 scale used in a population of Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2012, 22:877.
41. Corrado G., Lissoni A., Beretta S., et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol 2002, 89(7):838-841.
42. Spurney C., Shimizu R., Morgenroth L.P., Kolski H., Gordish-Dressman H., Clemens P.R. Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 2014, 50(2):250-256.
43. West N.A., Yang M.L., Weitzenkamp D.A., et al. Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J Pediatr 2013, 163(6):1759-1763.
44. Townsend D., Yasuda S., Chamberlain J., Metzger J.M. Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy. Trends Cardiovasc Med 2009, 19(2):50-55.
45. Birnkrant D.J., Ashwath M.L., Noritz G.H., et al. Cardiac and pulmonary function variability in Duchenne/Becker muscular dystrophy: an initial report. J Child Neurol 2010, 25(9):1110-1115.
46. Ahmad M., Sanderson J.E., Dubowitz V., Hallidie-Smith K.A. Echocardiographic assessment of left ventricular function in Duchenne's muscular dystrophy. Br Heart J 1978, 40(7):734-740.
47. Guell M.R., Avendano M., Fraser J., Goldstein R. Pulmonary and nonpulmonary alterations in Duchenne muscular dystrophy. Arch Bronconeumol 2007, 43(10):557-561.
48. Bianchi M.L., Biggar D., Bushby K., Rogol A.D., Rutter M.M., Tseng B. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord 2011, 21(4):298-303.
49. Rutter M.M., Collins J., Rose S.R., et al. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord 2012, 22(12):1046-1056.